Stockscreener 앱 받기
39.39
1.03%
0.4119
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Epidemic Keratoconjunctivitis Market Expected to Reach Huge - openPR
Xenon Pharmaceuticals announces executive changes - MSN
Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Assenagon Asset Management S.A. Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
How To Trade (XENE) - Stock Traders Daily
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
Xenon Pharmaceuticals Inc. Announces Cessation of Christopher Von Seggern as Chief Commercial Office - Marketscreener.com
Barclays PLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Barclays PLC Acquires 13,903 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential - Seeking Alpha
XENE Crosses Above Key Moving Average Level - Nasdaq
Xenon Pharmaceuticals Inc (XENE-Q) QuotePress Release - The Globe and Mail
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones - TipRanks
Xenon Outlines Key Corporate Milestone Opportunities for 2025 - The Manila Times
Traders Purchase High Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE) - MarketBeat
Investors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Trading (XENE) With Integrated Risk Controls - Stock Traders Daily
Dravet Syndrome Thereapeutics Market Size, Future Consumer Behavior and Market Dynamics (2024-2034) - 100×100 Música
Xenon to Showcase Innovations at J.P. Morgan Healthcare Conference - TipRanks
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
JPMorgan Chase & Co. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
JPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Barclays PLC - MarketBeat
Barclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
State Street Corp Boosts Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE) - Defense World
Stifel Financial Corp Has $849,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Franklin Resources Inc. - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 Shares - MarketBeat
Xenon Pharmaceuticals CFO sells shares worth $770,911 - Investing.com
Xenon Pharmaceuticals CFO sells shares worth $770,911 By Investing.com - Investing.com UK
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1%Here's Why - MarketBeat
BNP Paribas Financial Markets Reduces Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals participates in a conference call with William Blair - Nasdaq
(XENE) Trading Advice - Stock Traders Daily
Citigroup Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy Recommendation - MSN
Lord Abbett & CO. LLC Trims Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook - Investing.com India
Xenon Pharmaceuticals' SWOT analysis: azetukalner potential drives stock outlook By Investing.com - Investing.com Australia
Xenon Pharmaceuticals’ (XENE) Buy Rating Reiterated at HC Wainwright - Defense World
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? - MSN
XENE Makes Notable Cross Below Critical Moving Average - Nasdaq
Xenon Pharmaceuticals (NASDAQ:XENE) Earns Buy Rating from HC Wainwright - MarketBeat
Wellington Management Group LLP Buys 15,226 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
Two Sigma Advisers LP Buys 64,800 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - MarketBeat
(XENE) Technical Data - Stock Traders Daily
0.98%
7.55%
자본화:
|
볼륨(24시간):